Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1990 2
2000 1
2002 1
2003 2
2006 1
2014 1
2015 3
2016 1
2019 2
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

13 results
Results by year
Filters applied: . Clear all
Page 1
Trimetazidine and cardioprotection: facts and perspectives.
Tsioufis K, Andrikopoulos G, Manolis A. Tsioufis K, et al. Angiology. 2015 Mar;66(3):204-10. doi: 10.1177/0003319714530040. Epub 2014 Apr 8. Angiology. 2015. PMID: 24719262 Review.
Trimetazidine (TMZ) is a metabolic agent used in cardiology for more than 40 years. Several studies assessed the cardioprotective effects of TMZ in patients with chronic coronary heart disease (CHD) as well as in patients with heart failure (HF). ...According to the
Trimetazidine (TMZ) is a metabolic agent used in cardiology for more than 40 years. Several studies assessed the cardioprotective
Trimetazidine in cardiovascular medicine.
Marzilli M, Vinereanu D, Lopaschuk G, Chen Y, Dalal JJ, Danchin N, Etriby E, Ferrari R, Gowdak LH, Lopatin Y, Milicic D, Parkhomenko A, Pinto F, Ponikowski P, Seferovic P, Rosano GMC. Marzilli M, et al. Int J Cardiol. 2019 Oct 15;293:39-44. doi: 10.1016/j.ijcard.2019.05.063. Epub 2019 May 24. Int J Cardiol. 2019. PMID: 31178223 Review.
For these reasons, several studies have explored the potential benefits of trimetazidine (TMZ), an inhibitor of free fatty acids oxidation that shifts cardiac and muscle metabolism to glucose utilization. Because of its mechanism of action, TMZ has been found to provide a …
For these reasons, several studies have explored the potential benefits of trimetazidine (TMZ), an inhibitor of free fatty acids oxid …
The protective effect of trimetazidine on myocardial ischemia/reperfusion injury through activating AMPK and ERK signaling pathway.
Liu Z, Chen JM, Huang H, Kuznicki M, Zheng S, Sun W, Quan N, Wang L, Yang H, Guo HM, Li J, Zhuang J, Zhu P. Liu Z, et al. Metabolism. 2016 Mar;65(3):122-30. doi: 10.1016/j.metabol.2015.10.022. Epub 2015 Oct 19. Metabolism. 2016. PMID: 26892523 Free PMC article.
Intriguingly, the administration of ERK inhibitor, PD98059, to AMPK KD mice abolished the cardioprotection of TMZ against I/R injury. ...Therefore, both AMPK and ERK signaling pathways mediate the cardioprotection of TMZ against ischemic injury. The metabolic benefi …
Intriguingly, the administration of ERK inhibitor, PD98059, to AMPK KD mice abolished the cardioprotection of TMZ against I/R injury. …
Trimetazidine ameliorates sunitinib-induced cardiotoxicity in mice via the AMPK/mTOR/autophagy pathway.
Yang Y, Li N, Chen T, Zhang C, Liu L, Qi Y, Bu P. Yang Y, et al. Pharm Biol. 2019 Dec;57(1):625-631. doi: 10.1080/13880209.2019.1657905. Pharm Biol. 2019. PMID: 31545912 Free PMC article.
Trimetazidine (TMZ) is an anti-angina agent that has been demonstrated cardioprotective effects in numerous cardiovascular conditions, but its potential effects in SU-induced cardiotoxicity have not been investigated. ...Discussion and conclusions: Our result
Trimetazidine (TMZ) is an anti-angina agent that has been demonstrated cardioprotective effects in numerous cardiovascu
Cardioprotective effects of trimetazidine: a review.
Marzilli M. Marzilli M. Curr Med Res Opin. 2003;19(7):661-72. doi: 10.1185/030079903125002261. Curr Med Res Opin. 2003. PMID: 14606990 Review.
The efficacy of trimetazidine, an anti-ischaemic agent, has been largely assessed and presented in the international literature through its metabolic effects, selective and specific fatty acid oxidation inhibition and lack of haemodynamic effects in stable angina
The efficacy of trimetazidine, an anti-ischaemic agent, has been largely assessed and presented in the international literature throu …
Trimetazidine reduces oxidative stress in cardiac surgery.
Iskesen I, Saribulbul O, Cerrahoglu M, Var A, Nazli Y, Sirin H. Iskesen I, et al. Circ J. 2006 Sep;70(9):1169-73. doi: 10.1253/circj.70.1169. Circ J. 2006. PMID: 16936431 Free article. Clinical Trial.
BACKGROUND: Trimetazidine is an anti-ischemic agent that is used to treat angina and it has cardioprotective effects without inducing any significant hemodynamic changes. ...CONCLUSION: The findings suggest that pretreatment with trimetazidine alleviat …
BACKGROUND: Trimetazidine is an anti-ischemic agent that is used to treat angina and it has cardioprotective effects wi …
Clinical benefits of a metabolic approach in the management of coronary patients.
Marzilli M. Marzilli M. Rev Port Cardiol. 2000 Nov;19 Suppl 5:V25-30. Rev Port Cardiol. 2000. PMID: 11206100 Review.
Patients with Angina Pectoris benefit from therapy with nitrates, beta-blockers, and calcium channel antagonists. All these drugs, through different action mechanisms, tend to reduce cardiac work and restore the balance between myocardial metabolic demand and blood …
Patients with Angina Pectoris benefit from therapy with nitrates, beta-blockers, and calcium channel antagonists. All these dr …
Role of Trimetazidine in Ischemic Preconditioning in Patients With Symptomatic Coronary Artery Disease.
Costa LM, Rezende PC, Garcia RM, Uchida AH, Seguro LF, Scudeler TL, Bocchi EA, Krieger JE, Hueb W, Ramires JA, Filho RK. Costa LM, et al. Medicine (Baltimore). 2015 Aug;94(33):e1161. doi: 10.1097/MD.0000000000001161. Medicine (Baltimore). 2015. PMID: 26287407 Free PMC article.
Ischemic preconditioning (IP) is a powerful cardioprotective cellular mechanism that has been related to the "warm-up phenomenon" or "walk-through" angina, and has been documented through the use of sequential exercise tests (ETs). ...The purpose of this article is …
Ischemic preconditioning (IP) is a powerful cardioprotective cellular mechanism that has been related to the "warm-up phenomenon" or …
Trimetazidine limits the effects of myocardial ischaemia during percutaneous coronary angioplasty.
Poloński L, Dec I, Wojnar R, Wilczek K. Poloński L, et al. Curr Med Res Opin. 2002;18(7):389-96. doi: 10.1185/030079902125001146. Curr Med Res Opin. 2002. PMID: 12487504 Clinical Trial.
Angina and rhythm disturbances were more frequent in the control group. Time from balloon inflation to onset of angina was 50 +/- 26.2 s with trimetazidine vs. 32 +/- 15.0 s, for control group (p = 0.03). The time to pain relief after deflation was 19.3 +/- 1
Angina and rhythm disturbances were more frequent in the control group. Time from balloon inflation to onset of angina was 50
Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy.
Brottier L, Barat JL, Combe C, Boussens B, Bonnet J, Bricaud H. Brottier L, et al. Eur Heart J. 1990 Mar;11(3):207-12. doi: 10.1093/oxfordjournals.eurheartj.a059685. Eur Heart J. 1990. PMID: 2318223 Clinical Trial.
Trimetazidine (TMZ) has been shown to have anti-ischaemic properties improving exercise tolerance without haemodynamic effects. ...All patients had severe ischaemic cardiomyopathy, confirmed by coronary angiography; six were in NYHA class IV; 14 in NYHA class III; four had
Trimetazidine (TMZ) has been shown to have anti-ischaemic properties improving exercise tolerance without haemodynamic effects. ...Al
13 results
Jump to page
Feedback